Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp in Acute Vulvovaginal Candidiasis (VANISH-303)
NCT03734991Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vulvovaginal candidiasis (VVC) comparing Ibrexafungerp with Placebo (2 arms). Primary endpoint: Clinical Cure (Complete Resolution of Signs and Symptoms). Started Jan 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03734991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734991.